Serum Levels of Beta2-Microglobulin and Free Light Chains of Immunoglobulins Are Associated with Systemic Disease Activity in Primary Sjögren’s Syndrome. Data at Enrollment in the Prospective ASSESS Cohort
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To analyze the clinical and immunological characteristics at enrollment in a large prospective cohort of patients with primary Sjögren's syndrome (pSS) and to investigate the association between serum BAFF, beta2-microglobulin and free light chains of immunoglobulins and systemic disease activity at enrollment. METHODS: Three hundred and ninety five patients with pSS according to American-European Consensus Criteria were included from fifteen centers of Rheumatology and Internal Medicine in the "Assessment of Systemic Signs and Evolution of Sjögren's Syndrome" (ASSESS) 5-year prospective cohort. At enrollment, serum markers were assessed as well as activity of the disease measured with the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI). RESULTS: Patient median age was 58 (25(th)-75(th): 51-67) and median disease duration was 5 (2-9) years. Median ESSDAI at enrollment was 2 (0-7) with 30.9% of patients having features of systemic involvement. Patients with elevated BAFF, beta2-microglobulin and kappa, lambda FLCS had higher ESSDAI scores at enrollment (4 [2]-[11] vs 2 [0-7], P = 0.03; 4 [1]-[11] vs 2 [0-7], P< 0.0001); 4 [2]-[10] vs 2 [0-6.6], P< 0.0001 and 4 [2-8.2] vs 2 [0-7.0], P = 0.02, respectively). In multivariate analysis, increased beta2-microglobulin, kappa and lambda FLCs were associated with a higher ESSDAI score. Median BAFF and beta2-microglobulin were higher in the 16 patients with history of lymphoma (1173.3(873.1-3665.5) vs 898.9 (715.9-1187.2) pg/ml, P = 0.01 and 2.6 (2.2-2.9) vs 2.1 (1.8-2.6) mg/l, P = 0.04, respectively). CONCLUSION: In pSS, higher levels of beta2-microglobulin and free light chains of immunoglobulins are associated with increased systemic disease activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jonsson, M. V., Szodoray, P., Jellestad, S., Jonsson, R., & Skarstein, K. (2005) · Journal of Clinical Immunology · doi:10.1007/s10875-005-4091-5 · Cited by 229 · cited 4×
“BAFF is secreted not only by monocytes and dendritic cells but also by T and B lymphocytes and salivary gland epithelial cells in pSS [8–11].”
Influential
Cited by
Brito-Zerón, P., Baldini, C., Bootsma, H., Bowman, S. J., Jonsson, R., Mariette, X., Sivils, K., Theander, E., Tzioufas, A., & Ramos-Casals, M. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.47 · Cited by 868
Self-citationAdvances in understanding the pathogenesis of primary Sjögren's syndrome
Nocturne, G., & Mariette, X. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.110 · Cited by 404
Self-citationEULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide
Seror, R., Bowman, S. J., Brito-Zeron, P., Theander, E., Bootsma, H., Tzioufas, A., Gottenberg, J.-E., Ramos-Casals, M., Dörner, T., Ravaud, P., et al. (2015) · RMD Open · doi:10.1136/rmdopen-2014-000022 · Cited by 398
Self-citationB cells in the pathogenesis of primary Sjögren syndrome
Nocturne, G., & Mariette, X. (2018) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2018.1 · Cited by 351
Self-citationMariette, X., Seror, R., Quartuccio, L., Baron, G., Salvin, S., Fabris, M., Desmoulins, F., Nocturne, G., Ravaud, P., & De Vita, S. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203991 · Cited by 329
Self-citationSeror, R., Bootsma, H., Saraux, A., Bowman, S. J., Theander, E., Brun, J. G., Baron, G., Le Guern, V., Devauchelle-Pensec, V., Ramos-Casals, M., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206008 · Cited by 316
Self-citationGottenberg, J.-E., Ravaud, P., Puéchal, X., Le Guern, V., Sibilia, J., Goeb, V., Larroche, C., Dubost, J.-J., Rist, S., Saraux, A., et al. (2014) · JAMA · doi:10.1001/jama.2014.7682 · Cited by 311
Self-citationRediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases
Argyropoulos, C. P., Chen, S. S., Ng, Y.-H., Roumelioti, M.-E., Shaffi, K., Singh, P. P., & Tzamaloukas, A. H. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00073 · Cited by 308
Sjögren Syndrome‐associated lymphomas: an update on pathogenesis and management
Nocturne, G., & Mariette, X. (2015) · British Journal of Haematology · doi:10.1111/bjh.13192 · Cited by 295
Self-citationCancer and autoimmune diseases
Giat, E., Ehrenfeld, M., & Shoenfeld, Y. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.07.022 · Cited by 202
“Another study [45] based on the ASSESS cohort has shown BAFF and beta2-microglobulin to be higher in pSS patients with lymphoma (1173.”
ResultDörner, T., Posch, M. G., Li, Y., Petricoul, O., Cabanski, M., Milojevic, J. M., Kamphausen, E., Valentin, M.-A., Simonett, C., Mooney, L., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214720 · Cited by 192
Metadata
- Authors
- Gottenberg, J.-E., Seror, R., Miceli-Richard, C., Benessiano, J., Devauchelle-Pensec, V., Dieude, P., Dubost, J.-J., Fauchais, A.-L., Goeb, V., Hachulla, E., Hatron, P. Y., Larroche, C., Le Guern, V., Morel, J., Perdriger, A., Puéchal, X., Rist, S., Saraux, A., Sene, D., Sibilia, J., Vittecoq, O., Nocturne, G., Ravaud, P., & Mariette, X.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-24
- Volume
- 8
- Issue
- 5
- Pages
- e59868
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2022755336
- Cited by
- 186
- References
- 1
- FWCI
- 10.41
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.